PGY2 Oncology Pharmacy Residency Program Overview
2016-2017

National Matching Service Code: 619860
https://health.ucsd.edu/specialties/pharmacy/residency/Pages/hem-onc.aspx

The UC San Diego Health Department of Pharmacy and the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS) offers a one-year specialty residency in oncology pharmacy practice beginning August 1, 2016.

Purpose:
Pharmacy residents completing the UC San Diego Postgraduate Year Two (PGY2) Oncology Pharmacy Practice Residency will be described as advanced practitioners who are equipped to be fully integrated members of the interdisciplinary hematology/oncology team and able to make complex medication, including chemotherapy, recommendations in this environment. The resident will engage in various learning experiences, allowing them to understand and appreciate the implications of medication therapy used in various disease states commonly encountered in this patient population. At the completion of the PGY2, the resident will have mastered the skills of writing and evaluating a chemotherapy order; in addition to managing preparation, distribution, and disposal of hazardous medications. They will demonstrate leadership and practice management skills, and develop proficiency in communication through educating other health care professionals, patients, and students on hematology/oncology issues. Graduates of our program will have developed the skills necessary to conduct a hematology/oncology pharmacy research project, precept students/residents, and serve on a multidisciplinary committee. These marketable job skills will prepare the resident for career opportunities in any hematology/oncology setting for any health care organization and provide the background necessary to achieve board certification in oncology.

Program Description:
UC San Diego health PGY2 oncology pharmacy residency program prepares its graduates to assume positions in oncology areas as a clinical specialist employed by an institution or as assistant professors at a college of pharmacy. Graduates will be prepared to sit for the Board Certification Oncology Pharmacy exam. UC San Diego Health is a university teaching hospital providing the unique capability to engage each of our residents in direct patient care activities across a vast array of disease states, research, administration and project management, and multidisciplinary teaching skills.

PGY2 residents will gain the skills to function as the primary oncology pharmacist during their required core rotations. Primary responsibilities vary based on rotation and include rounding with the oncology/hematology/bone marrow transplant disease specific teams (inpatient and outpatient), designing, recommending, monitoring, and evaluating patient-specific therapeutic regimens that incorporate the principles of evidence-based medicine, addressing all pharmacokinetically-monitored medications, acting as secretary of the hematology/oncology Pharmacy & Therapeutics subcommittee, validating pharmacy orders for oncology patients (including chemotherapy), and overseeing and directing PGY1 resident and pharmacy student activities. This integration of staffing and clinical services prepares residents for any type of practice environment they may encounter in their future jobs by emphasizing the development of essential skills required for an advanced pharmacy practitioner: independent practice skills, multi-tasking and prioritization.

Teaching activities include regular didactic presentations, leading oncology topic discussions for fourth year pharmacy students, involvement with UCSD SSPPS courses (e.g., conference leader for third year therapeutics course, lecturer for oncology elective and therapeutics course (if available)), and as warranted clerkship preceptorship of PGY1 pharmacy practice residents and fourth-year UCSD pharmacy students. The ability to work independently and to supervise pharmacy students and residents will be emphasized. The resident will also be involved in a research project. Scientific writing is strongly emphasized and the preparation of a manuscript suitable for publication will be expected, and submission to a journal strongly encouraged.
Number of residency positions available: 1 resident is typically accepted each year

House Officer Details:
The annual stipend is currently $52,000. Benefits include medical, dental, and vision insurance. In addition, vacation, sick and professional leave are provided. Please visit the UC San Diego Health Pharmacy Residency webpage for more information about duty hours, leave, benefits, position description, terms of dismissal, and more. Click on the House Officer Policy and Procedure Document: https://health.ucsd.edu/specialties/pharmacy/residency/Pages/Salary-and-Benefits.aspx

Requirements:
All applicants will be contacted for a preliminary phone interview in early January. On-site interviews will be held during late January through early March. This specialty residency program participates in the ASHP Resident Matching Program. All applicants must be enrolled in the Resident Matching Program. To facilitate this enrollment process and for further information, please visit the following website: www.natmatch.com/ashprmp

If matched with the UC San Diego Residency Program, matched candidates must have all of the following:
1. Graduated from an accredited school of pharmacy with a Doctor of Pharmacy degree
2. Successfully completed an accredited PGY1 pharmacy practice residency
3. Obtained California pharmacy licensure prior to beginning residency (absolute deadline to start = November 1st). The residency offer may be rescinded if the resident does not take the CPJE prior to August 1st or does not pass the CPJE on the first attempt.

Application:
Applications for the 2016-2017 year will be accepted beginning December 1, 2015. Deadline for application is January 4, 2016. Applications should be submitted through PhORCAS and include the following:
1. Letter of intent.
2. Current Curriculum Vitae
3. Three electronic references are required.

Program Structure:
Rotations:
Descriptions of each learning experience can be found in PharmAcademic

Half of the year will focus on outpatient and half will focus on inpatient.

1 week of orientation
2-3 weeks of inpatient training
4 months inpatient
   ▪ 2 months inpatient hematology/oncology consult (CORE required rotation)
   ▪ 2 months inpatient hematology hematopoetic stem cell transplant (CORE required rotation)
4 months outpatient
   ▪ 1 month outpatient infusion center (serves as orientation to outpatient staffing)
   ▪ 3 months outpatient clinics
2, 1 month long electives
Approximately 4 weeks of research time

Elective Choices:
Descriptions of each learning experience can be found in PharmAcademic
There will be a total of 5 rotations that the resident can choose their 2 electives from. Any of the required rotations could be repeated again as an elective.
• Pain Management & Palliative Care
• Investigational Drug Service
• Cancer Center Retail Pharmacy
• Infectious Diseases
• Cancer Center Administration
Rotation Schedule Example:
O=orientation, E=elective, C=core required rotation, R=research

<table>
<thead>
<tr>
<th>Month</th>
<th>Rotation</th>
</tr>
</thead>
<tbody>
<tr>
<td>August</td>
<td>Outpatient Infusion Center (O)</td>
</tr>
<tr>
<td>September</td>
<td>Pain &amp; Palliative Care (E)</td>
</tr>
<tr>
<td>October</td>
<td>Outpatient Clinic (C)</td>
</tr>
<tr>
<td>November</td>
<td>Outpatient Clinic (C)</td>
</tr>
<tr>
<td>December</td>
<td>Inpatient Orientation (O)</td>
</tr>
<tr>
<td>January</td>
<td>Inpatient Oncology (C)</td>
</tr>
<tr>
<td>February</td>
<td>Research (R)</td>
</tr>
<tr>
<td>March</td>
<td>Inpatient BMT (C)</td>
</tr>
<tr>
<td>April</td>
<td>Inpatient BMT (C)</td>
</tr>
<tr>
<td>May</td>
<td>Outpatient Clinic (C)</td>
</tr>
<tr>
<td>June</td>
<td>Elective (E), such as IDS</td>
</tr>
<tr>
<td>July</td>
<td>Inpatient Oncology (C)</td>
</tr>
</tbody>
</table>

Research Project:
The resident will be involved with 2 projects throughout the academic year. The idea is that they will be completing an ongoing project which will be presented at the either Western States Conference or at a national oncology meeting (i.e. Hematology/Oncology Pharmacy Association (HOPA), American Society of Clinical Oncology (ASCO), etc) as well as initiating a second project. This initiation phase will be to define the study design, write up the protocol and begin the IRB approval phase for the incoming PGY2 Onc’s research project. The idea here is that the incoming oncology resident will then finish the project that was started during the previous year. A list of project ideas will be generated from the core preceptors and the selection of the project the resident will complete will need to be completed within 1-2 months of start date. The generation of research ideas that will be the focus of their 2nd project will need to begin soon after starting the residency.

Other Projects:
The resident will be asked to complete multiple mini-projects throughout the PGY2 year. Some will focus on formulary management & quality improvement; others may be to initiate new protocols or guidelines. These projects will be formulated through their involvement in the Hematology/Oncology Subcommittee of the Pharmacy & Therapeutics Committee or during their inpatient/outpatient months.

Practice Management Experience:
The PGY2 resident will be required to staff 16 weekends (which includes 1 minor holiday weekend and 1 major holiday (Thanksgiving, Christmas, or New Years) at UCSD, and the possibility of a weekday staffing component during certain rotations. The weekday staffing would be inpatient staffing after rotation, one day per week, to allow the resident to gain more experience with chemotherapy order evaluation and to experience the differences between weekday and weekend staffing. The resident will get 13 paid days for holidays and 12 sick days for the academic year. Vacation time will be in accordance with GME rules and will be defined as 20 days of vacation PLUS 5 days for professional leave to attend meetings or conferences.

Please refer to UCSD Medical Center’s Terms and Conditions of Employment for House officers for more detailed information regarding benefits. This has been adapted based upon the GME requirements for training. (http://ogme.ucsd.edu)
PGY2 resident must be a licensed pharmacist in state of California on or before start date of PGY2 year and have successfully completed PGY1 pharmacy residency at an ASHP accredited program. Failure to comply with these requirements may result in dismissal from the program. If not licensed by November 1, offer is rescinded.

Completion of PGY2 pharmacy residency requires 80% of goals to be achieved by end of year and no goals indicating Needs Improvement.

**Presentations and Teaching**

The residents will be required to give many educational lectures to their colleagues throughout their residency year. The following details some of these events:

**Grand Rounds:**
The resident will be delivering a 1-hour CE lecture to the pharmacy staff regarding a new drug, new guidelines, controversial topic in hematology/oncology or other topic approved by PGY2 Onc Director.

If there are 2 hematology/oncology PGY2 resident(s), they can present individual topics at separate times of the year or they could present a controversial topic together (taking opposing stances). The idea behind a joint presentation isn't to antagonize each other but to deliver an unbiased complete presentation of the controversial topic diving into the pertinent literature that supports their viewpoint and counters their opponents. The residents will have rehearsed their presentation together ahead of time in order to provide a seamless educational lecture.

**Monthly Didactic Forums – BCOP Lecture Series:**
In addition to the grand rounds, the resident(s) will be required to research and deliver two or three 45-60-minute lectures on various didactic topics throughout the year. These topics will be related to the BCOP Preparatory Review Course and will be relevant to the patient population they are currently involved with from a rotational perspective when possible. All parties are welcome to attend but the core hematology/oncology staff are strongly recommended to attend. This lecture series is held in conjunction with the San Diego Veteran’s Affairs and Kaiser Permanente PGY2 Onc residents, along with the UCSD Skaggs School of Pharmacy/Pfizer fellows, giving the residents/fellows the opportunity to mingle with other oncology pharmacists in the area.

**Drug Review:**
During outpatient blocks resident will go through various classes of anti-neoplastic agents. This will be an informal presentation to inpatient/outpatient preceptor including mechanism of action, pharmacokinetics, adverse effects, drug interactions, counseling pearls, etc.

**Journal Club:**
We will also be conducting a hematology/oncology journal club where the resident(s) will be required to present 4 articles by the end of the year. These meetings will be scheduled during the inpatient (2 articles) and outpatient (2 articles) rotation blocks and the date/location will be announced during the preceding week or so.

**Skagg’s School of Pharmacy and Pharmaceutical Sciences (SSPPS):**
The resident’s involvement with UCSD’s School of Pharmacy will vary depending on requests from SSPPS but possible activities include writing up hematology/oncology cases for student case conference, co-leading a case conference section with another PGY1 or PGY2 resident, preparing exam questions based on the hematology/oncology lectures presented, and/or presenting a formal lecture on hematology/oncology or another topic. Involvement beyond this would be directly related to precepting a student if they are on a rotation with the resident.

**Publication:**
Scientific writing is strongly emphasized and the preparation of a manuscript suitable for publication will be expected, and submission to a journal strongly encouraged. The purpose of this requirement will be
the development of scientific writing skills and communication skills. The types of publishable literature can include any of the following types of manuscripts:

- Case reports with a review of the literature
- Primary research/original research
- Medication Use Evaluation
- Meta-analysis of a disease state or therapy
- Review article

**Meetings:**

The resident will attend a profession meeting during their PGY2 year. The UCSD program will grant the resident a travel stipend to be used as reimbursement for attendance at a specialty meeting (i.e. annual meetings for HOPA, ASCO, ASH, NCCN, etc.) or the resident may choose to attend California Society of Health System’s Pharmacist (CSHP), American Society of Health Systems Pharmacists (ASHP) midyear meeting or Western States Conference. Their research project must be presented at either the specialty meeting or Western States Conference. A resident may, upon request, be granted the opportunity to attend more than 1 of the meetings above but any reimbursement beyond the travel budget will be the responsibility of the resident.

**Assessment Strategy – PharmAcademic:**

The PGY2 Oncology Specialty Residency Program uses the ASHP on-line evaluation tool called PharmAcademic, which is available for all ASHP-accredited pharmacy residency programs. This system, which is technologically supported by the McCreddie Group, supports the ASHP Residency Learning System (RLS).

Residents who are matched with this PGY2 specialty program are entered into PharmAcademic prior to their arrival in August. The incoming resident completes two pre-residency questionnaires that help the Residency Program Director (RPD) design a residency year that is tailored to the specific needs and interests of the resident:

- ASHP Standard Entering Interests Form
- Goal-Based Entering Interests Form

Residents’ schedules and assigned RLS Goals are entered into PharmAcademic. We have chosen to use the PharmAcademic evaluation tools for our Learning Experiences. For each Learning experience, the following Assessments are completed:

- Preceptor Assessment of Resident: Summative (for each Learning experience)
- Resident Self-Assessment: Summative-self (for each Learning experience)
- Resident Assessment of the Learning Experience
- Resident assessment of Preceptor

Preceptors and residents are encouraged to exchange in on-going, daily verbal feedback throughout each rotation experience. The Resident and Preceptors are trained and reminded throughout the year to complete evaluations in a thorough (quantitatively and qualitatively) and timely manner. To this end, evaluations may be used, not only as assessment tools, but as tools that Preceptors may turn to for help in guiding Residents to improve, grow and achieve the residency programs and the residents’ goals and objectives for the residency year. The RPD reviews all evaluations and solicits verbal feedback from preceptors and residents to provide guidance to help the resident maximize the residency experience.

The Residents discuss their Program goals and interests quarterly (Quarterly Update and Customized Training Plan) with the RPD to evaluate where they are in meeting the residency goals and to set or modify goals for the remaining months of the residency program. Residents may meet as needed as their interests change throughout the year. The resident may request schedule modifications throughout the residency year and the RPD will make all efforts to accommodate these requests. Assessment tools will be adjusted as changes are made.
The Resident completes the ASHP PharmAcademic exit evaluation. Residents also are requested to complete a year-long evaluation of the Residency Program by indicating pros/cons of each rotation. This document is to be updated at the end of each rotation rather than at the end of the year.

The results of these year-end Program evaluations are reviewed by the RPD for potential merit and potential action plans are developed in an effort to achieve continuous quality improvement.

**Assessment Overview**  
*(PGY2 Oncology)*

*It is the resident's responsibility to ensure the timely completion of all evaluations. Self reflection is encouraged to be included in Summative Evaluation of Resident for each rotation.*

<table>
<thead>
<tr>
<th>Learning Experience</th>
<th>Frequency</th>
<th>Type of Assessment</th>
<th>Summative-preceptor</th>
<th>Summative-self</th>
<th>Resident Assessment of Preceptor and Learning Experience</th>
<th>Custom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orientation Inpatient</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MCC Infusion Center</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Outpatient Clinic #1</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Outpatient Clinic #2</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Outpatient Clinic #3</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Inpatient Oncology</td>
<td>Midpoint and Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Inpatient BMT</td>
<td>Midpoint and Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Research Month</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pain &amp; Palliative Care</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>MCC Retail Pharmacy</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Investigational Drug Service</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Cancer Center Administration</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>Final</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Inpatient Staffing</td>
<td>Quarterly</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Outpatient Staffing</td>
<td>Quarterly</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Hem/Onc P&amp;T Subcommittee</td>
<td>Quarterly</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Presentations</td>
<td>Quarterly</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Research Project/Publication</td>
<td>Quarterly</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

**PGY2 Oncology Competency Areas, Goals and Objectives:**

- Educational Outcome: broad categories of the residency graduates’ capabilities.
  - Outcome R1: Serve as an authoritative resource on the optimal use of medications used to treat individuals with cancer.
Outcome R2: Optimize the outcomes of the care of individuals with cancer by providing evidence-based, patient-centered mediation therapy as an integral part of an interdisciplinary team.

Outcome R3: Manage and improve the medication-use process in oncology patient care areas.

Outcome R4: Demonstrate excellence in the provision of training or educational activities for health care professionals or health care professionals in training.

Outcome R5: Promote health improvement, wellness, and cancer prevention.

Outcome R6: Sustain the ongoing development of expertise and professionalism in the practice of oncology pharmacy.

Outcome R7: Conduct oncology pharmacy practice research.

Outcome R8: Function effectively in oncology settings participating in clinical investigations.

- Educational Goals: Goals listed under each outcome are broad sweeping statements of abilities.
- Educational Objectives: Resident achievement of educational goals is determined by assessment of the resident’s ability to perform the associated educational objective below each educational goal.
- The resident is encouraged to read detailed information about each goal at the ASHP website (click on Critical Care Pharmacy (PGY2), 2007) https://www.ashp.org/Professional-Development/Residency-Information/Residency-Program-Directors/Residency-Accreditation/PGY2-Competency-Areas
- For information about Goals and Objectives Taught/Taught and Evaluated in Learning Experiences, please visiting PharmAcademic, go the ‘Reports’ tab, and click on ‘Goals and Objectives Taught/Taught and Evaluated in Learning Experiences’.

**PGY2 Oncology Residency Requirements for Completion/Graduation:**

- Successful completion of all core rotations (all rotation goals marked SP or ACH by the final evaluation)
- ≥80% of RLS goals marked “Achieved for the Residency” by the end of the year (as evaluated by individual rotation preceptors or by the RPD upon final review of the resident’s progress)
- Completion of required presentations: 4 Journal Clubs, 1 Grand Rounds, 2 Drug Topic Discussions, BCOP lectures, monograph, 1 inservice
- Completion of a residency project; including presentation at a suitable conference/meeting
- Submission of a manuscript suitable for publication
- Participation in Therapeutics Conference as a facilitator
- Twelve months maximum is allotted to successfully complete the core requirements. If a core rotation must be repeated, then elective time shall be used. If the above requirements are not met in full, the residency certificate may be withheld at the discretion of the residency director.